NEXTBIO CAPITAL MANAGEMENT LP
Q2 2026 Form 13-F
MENLO PARK, DELAWARE
CIK 0002038158
· Institutional investment manager
$217.4M Reported Value Total
Reported value
$217.4M
Quarter over quarter
+15.3%
Holdings
22
Top-10 concentration
77.7%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Ky Phan
CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2026 13F record
Q2 2026 13F filing summary
| Period of report | June 30, 2026 |
|---|---|
| Filed | August 14, 2026 |
| Form | 13F-HR |
| Reported value | $217.4M |
| Positions | 22 |
| Change in reported value | +0.9% |
| New positions | 3 |
| Exited positions | 5 |
| Position turnover | 29.6% |
| Top-10 concentration | 77.7% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 13, 2026
|
25 | $234.4M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
22 | $217.4M |
|
Q1 2026 13F
Filed May 14, 2026
|
24 | $215.4M |
|
Q4 2025 13F
Filed Feb 13, 2026
|
23 | $170.5M |
Top 20 holdings · Q2 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | PTGX PROTAGONIST THERAPEUTICS INC | $26.9M | 12.37% |
| 2 | STTK SHATTUCK LABS INC | $25.9M | 11.9% |
| 3 | CMPS COMPASS PATHWAYS PLC | $25.1M | 11.56% |
| 4 | GPCR STRUCTURE THERAPEUTICS INC | $16.8M | 7.71% |
| 5 | VOR VOR BIOPHARMA INC | $16.4M | 7.53% |
| 6 | RYTM RHYTHM PHARMACEUTICALS INC | $14.6M | 6.73% |
| 7 | PVLA PALVELLA THERAPEUTICS INC NE | $13.7M | 6.32% |
| 8 | XENE XENON PHARMACEUTICALS INC | $11.1M | 5.09% |
| 9 | ZBIO ZENAS BIOPHARMA INC | $10.8M | 4.98% |
| 10 | ORIC ORIC PHARMACEUTICALS INC | $7.6M | 3.52% |
| 11 | IVA INVENTIVA SA | $6.8M | 3.11% |
| 12 | CBIO CRESCENT BIOPHARMA INC. | $6.7M | 3.09% |
| 13 | PCVX VAXCYTE INC | $6.2M | 2.87% |
| 14 | COGT COGENT BIOSCIENCES INC | $5.1M | 2.33% |
| 15 | VSTM VERASTEM INC | $5.0M | 2.3% |
| 16 | IRON DISC MEDICINE INC | $3.9M | 1.77% |
| 17 | PHVS PHARVARIS N V | $3.7M | 1.72% |
| 18 | ZLAB ZAI LAB LTD | $3.5M | 1.6% |
| 19 | BIOA BIOAGE LABS INC | $2.5M | 1.14% |
| 20 | LBRX LB PHARMACEUTICALS INC | $2.2M | 1.02% |
Values as reported on the Q2 2026 Form 13F. Every position is in the holdings table below.